This is not good.

"Changes to the primary end point during or after recruitment were omnipresent in randomized clinical trials with immune checkpoint inhibitors for patients with UC, RCC, and NSCLC. Most common were switching to or adding OS as an outcome measure and subpopulations based on PD-L1 expression. Ultimately, published data often do not allow readers to infer what the results would have been if the primary outcome had not been changed."

#Immunology #Immunotherapy #immunooncology #checkpointinhibitors

https://jamanetwork.com/journals/jamaoncology/fullarticle/2805960?guestAccessKey=c026475f-ec3b-48fb-886a-41ab2e638826&utm_source=linkedin_company&utm_medium=social_jamaonc&utm_term=10276892794&utm_campaign=article_alert&linkId=218897512